Big Tech firms are borrowing heavily to fund AI infrastructure. This shift from using cash reserves worries investors. The trend signals a new, riskier phase for AI. Companies with weaker finances are now involved. Interconnected deals create systemic risk. Valuations for major tech firms are also declining due to this unease.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt’s shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam,
June 1, 2026